Huachansu

DRUG4 trials

Sponsors

M.D. Anderson Cancer Center, Fudan University, Beijing Shenogen Biomedical Co., Ltd

Conditions

Carcinoma, HepatocellularEsophageal Squamous Cell CarcinomaHepatocellular CarcinomaPancreatic Cancer

Phase 2

Huachansu & Gemcitabine in Pancreatic Cancer

CompletedNCT00837239

M.D. Anderson Cancer CenterPancreatic Cancer

Start: 2007-06-30End: 2012-07-31Updated: 2012-07-12

Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase

Fudan UniversityCarcinoma, Hepatocellular

Start: 2012-07-31End: 2016-06-30Target: 120Updated: 2015-12-18

A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC

CompletedNCT02647125

Fudan UniversityEsophageal Squamous Cell Carcinoma

Start: 2015-09-30End: 2022-12-31Updated: 2024-11-26

Phase 3

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

RecruitingNCT05594927

Beijing Shenogen Biomedical Co., LtdHepatocellular Carcinoma

Start: 2022-12-12End: 2025-08-30Target: 261Updated: 2024-08-07

Related Papers

Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma.

2025-10-01

Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu – a single-center randomised controlled trial

BMJ Supportive & Palliative Care2023-07-038 citations